查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1917798

非PVC输液袋市场－2026-2031年预测

Non-PVC IV Bags Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 141 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

非PVC输液袋市场预计将从2025年的22.52亿美元成长到2031年的30.41亿美元，维持5.13%的复合年增长率。

受静脉输液治疗领域对更安全、更永续材料的根本性转变的推动，非聚氯乙烯（PVC）输液袋市场正经历显着成长。这些输液袋采用聚烯（乙烯-醋酸乙烯酯共聚物、聚丙烯）、聚氨酯和聚醚砜等替代聚合物製成，旨在消除传统聚氯乙烯（PVC）容器可能带来的健康和环境风险。市场扩张的驱动因素包括临床需求的成长、监管措施的严格性以及整个产业向环保型医疗解决方案的转型。

关键市场驱动因素与监管催化剂

慢性疾病在全球日益加重，需要长期、高强度的静脉输液治疗，这是成长要素。随着癌症、慢性肾臟病（CKD）和其他严重的盛行率不断上升，可靠地输注大量液体、化疗、肠外营养液和透析液至关重要。由于非聚氯乙烯（PVC）输液袋的材料惰性以及与多种药物製剂的相容性，它们越来越多地被用于这些应用，使其成为现代治疗通讯协定的关键组成部分。

推动市场转型的最有力、最直接的催化剂是全球针对邻苯二甲酸二(2-乙基己基)酯 (DEHP) 的监管行动。 DEHP 是一种常用的聚氯乙烯 (PVC)塑化剂。主要市场的监管机构已发布建议和限制，禁止在包括新生儿、孕妇和严重病人在内的弱势群体中使用含 DEHP 增塑剂的医疗设备。这些法规源于人们对 DEHP 渗出物的担忧，DEHP 渗出物可能导致代谢和发育障碍。这种监管压力正促使医疗机构寻求更安全的替代方案，从而推动采购方式的必要转变，并直接加速非 PVC 材质输液容器的普及。

同时，医疗保健产业日益增长的环境和永续性意识正在推动这种材料转变。 PVC废弃物对环境的影响，包括回收的挑战和潜在的毒素释放，促使医疗保健系统优先考虑更环保的采购政策。非PVC材料通常更容易回收利用，且不含卤代化合物，这与机构的永续性目标和企业社会责任（CSR）活动相一致——这是采购决策中一个重要的非临床因素。

临床和材料优势

除了符合监管要求外，非PVC输液袋还具有明显的临床和操作优势。其材质成分通常与某些敏感药物製剂具有更优异的相容性，包括某些脂质、紫杉烷类药物以及其他可能与PVC产生交互作用或被PVC吸收的药物。这降低了药物损失、疗效降低以及患者接触渗出的塑化剂的风险。对于医疗机构而言，这意味着更高的病人安全性、更少的药物废弃物以及更柔软性的药物储存和给药方式。

市场挑战与限制因素

转型面临诸多障碍。主要阻碍因素是非PVC材质造口袋的单位成本高于传统PVC造口袋。这种成本差异可能成为预算紧张的医疗系统，尤其是在价格敏感型市场的一大障碍。因此，必须透过减少併发症和永续性来清晰地证明其长期价值。

此外，PVC医疗设备成熟的全球製造基础设施使得市场快速转型举步维艰。替代聚合物的供应链必须达到类似的规模、可靠性和地理覆盖率才能满足全球需求。确保材料品质的稳定性以及应对检验新型容器-药物组合的复杂挑战，也需要製造商持续投入。

区域市场动态

由于严格的监管指导、医疗服务提供者的高度重视、有利的报销机制以及主要市场参与者的存在，北美预计将继续保持主导的市场份额。该地区对病人安全的重视，以及医疗保健领域积极的环境政策，为非PVC替代品的推广创造了高度友善的环境。欧洲的发展轨迹与之类似，深受欧盟医疗设备法规（MDR）等全面法规​​和强而有力的环境法规的影响。亚太地区拥有巨大的成长潜力，这得益于不断扩大的医疗基础设施、日益​​增长的治疗量以及监管标准和环保意识的逐步提高，儘管价格敏感性是一个更为突出的因素。

竞争格局与策略方向

该市场以众多大型医疗设备製造商为特征，这些製造商在输液治疗领域拥有丰富的产品系列。竞争主要集中在材料科学创新、药物相容性数据、供应链可靠性以及提供全面的非PVC解决方案的能力。策略性倡议包括投资先进的聚合物製造技术、获得特定高价值应用（例如肿瘤学、新生儿学）的监管核准，以及与製药製造商合作开发相容的包装系统。成功的关键在于展现临床优势、实现规模化成本效益，以及提供强而有力的教育支持，以帮助医疗专业人员顺利过渡。

总之，在不可逆转的监管和环境要求的推动下，非PVC输液袋市场正从利基替代方案转型为主流标准。其成长与慢性病管理中静脉输液疗法的普及以及医疗产业对更安全、更永续实践的承诺密切相关。对于业内专家而言，未来发展的关键在于持续改进材料技术以提高性能并降低成本，产生全面的临床数据以支援其广泛应用，以及应对复杂的全球监管环境以确保顺利市场进入。从长远来看，非PVC材料有望成为输液容器的主流标准，这反映了患者照护和环境保护领域不断变化的优先事项。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

5. 非PVC输液袋市场按类型划分

  • 介绍
  • 单室
  • 多重腔体

6. 非PVC输液袋市场（依材料划分）

  • 介绍
  • 乙烯-醋酸乙烯酯共聚物（EVA）
  • 聚丙烯（PP）
  • 共聚酯醚

7. 非PVC输液袋市场（以销量计）

  • 介绍
  • 50毫升或以下
  • 50～100 ml
  • 超过100毫升

8. 依最终用户分類的非PVC输液袋市场

  • 介绍
  • 医院
  • 专科诊所
  • 其他的

9. 非PVC输液袋市场（按地区划分）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十一章：公司简介

  • B. Braun SE
  • ICU Medical, Inc
  • Fresenius Kabi AG
  • Technoflex
  • Silica Healthcare Private Limited
  • Spirit Medical Limited
  • Ningbo Siny Medical Technology Co.
  • Rusoma Laboratories Private Limited

第十二章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615772

Non-PVC IV Bags Market, sustaining a 5.13% CAGR, is anticipated to reach USD 3.041 billion in 2031 from USD 2.252 billion in 2025.

The non-PVC IV bags market is experiencing significant growth, driven by a fundamental shift toward safer and more sustainable materials in intravenous therapy. These bags, constructed from alternative polymers such as polyolefins (ethylene-vinyl acetate, polypropylene), polyurethane, and polyethersulfone, are designed to eliminate the potential health and environmental concerns associated with traditional polyvinyl chloride (PVC) containers. The market's expansion is propelled by the convergence of rising clinical demand, stringent regulatory actions, and a broader industry movement toward eco-friendly healthcare solutions.

Core Market Drivers and Regulatory Catalysts

A primary growth driver is the escalating global burden of chronic diseases requiring intensive and long-term intravenous therapies. The rising prevalence of conditions such as cancer, chronic kidney disease (CKD), and other critical illnesses necessitates reliable, high-volume administration of fluids, chemotherapy, parenteral nutrition, and dialysis solutions. Non-PVC bags are increasingly specified for these applications due to their material inertness and compatibility with a wider range of drug formulations, making them a critical component in modern treatment protocols.

The most powerful and direct catalyst for market conversion is the global regulatory movement against di(2-ethylhexyl) phthalate (DEHP), a plasticizer commonly used to soften PVC. Regulatory bodies in major markets have issued advisories and restrictions on the use of DEHP-plasticized medical devices, particularly for vulnerable patient populations such as neonates, pregnant women, and critically ill individuals. These regulations stem from well-documented concerns over DEHP leaching, which can cause adverse metabolic and developmental effects. This regulatory pressure compels healthcare providers to seek safer alternatives, creating a mandatory shift in procurement and directly accelerating the adoption of non-PVC IV containers.

Concurrently, growing environmental and sustainability priorities within the healthcare sector are reinforcing this material transition. The environmental impact of PVC disposal, including challenges with recycling and potential release of toxins, has led healthcare systems to prioritize greener procurement policies. Non-PVC materials, which are often more readily recyclable and free of halogenated compounds, align with institutional sustainability goals and corporate social responsibility initiatives, adding an important non-clinical driver to the purchasing decision.

Clinical and Material Advantages

Beyond regulatory compliance, non-PVC IV bags offer distinct clinical and operational benefits. Their material composition generally provides superior compatibility with sensitive drug formulations, including certain lipids, taxanes, and other pharmaceuticals that can interact with or be absorbed by PVC. This reduces the risk of drug loss, potency reduction, and patient exposure to leached plasticizers. For healthcare facilities, this translates to enhanced patient safety, reduced medication waste, and greater flexibility in drug storage and administration.

Market Challenges and Restraints

The transition faces notable hurdles. A significant restraint is the higher unit cost of non-PVC bags compared to conventional PVC options. This cost differential can be a barrier for budget-constrained healthcare systems, particularly in price-sensitive markets, requiring a clear demonstration of long-term value through reduced complications and aligned sustainability benefits.

Furthermore, the entrenched, global manufacturing infrastructure for PVC medical devices presents a challenge to rapid market conversion. Supply chains for alternative polymers must achieve similar scale, reliability, and geographic penetration to meet global demand. Ensuring consistent material quality and navigating the complexities of validating new container-drug combinations also require ongoing investment from manufacturers.

Geographic Market Dynamics

North America is projected to maintain a leading market share, driven by a combination of stringent regulatory guidance, high awareness among healthcare providers, supportive reimbursement structures, and the presence of major market players. The region's focus on patient safety, coupled with proactive environmental policies in healthcare, creates a highly receptive environment for non-PVC alternatives. Europe follows a similar trajectory, heavily influenced by comprehensive regulations like the EU Medical Device Regulation (MDR) and strong environmental mandates. The Asia-Pacific region represents a high-growth opportunity, fueled by expanding healthcare infrastructure, increasing treatment volumes, and a gradual rise in regulatory standards and environmental awareness, though price sensitivity remains a more pronounced factor.

Competitive Landscape and Strategic Direction

The market is characterized by the presence of large, established medical device companies with extensive portfolios in infusion therapy. Competition centers on material science innovation, drug compatibility data, supply chain reliability, and the ability to offer a comprehensive range of non-PVC solutions. Strategic activities include investment in advanced polymer manufacturing, securing regulatory approvals for specific high-value applications (e.g., oncology, neonatology), and forming partnerships with drug manufacturers to develop compatible packaging systems. Success depends on demonstrating clinical superiority, achieving cost efficiencies at scale, and providing robust educational support to facilitate the transition for healthcare providers.

In conclusion, the non-PVC IV bags market is transitioning from a niche alternative to a mainstream standard, driven by an irreversible regulatory and environmental mandate. Its growth is structurally linked to the expansion of intravenous therapy across chronic disease management and the healthcare industry's commitment to safer, more sustainable practices. For industry experts, the critical path forward involves continuing to advance material technologies to improve performance and reduce costs, generating comprehensive clinical data to support broader adoption, and navigating the complex global regulatory landscape to ensure seamless market access. The long-term trajectory points toward non-PVC materials becoming the dominant standard for IV containment, reflecting the evolving priorities of patient care and environmental stewardship.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Non-PVC IV Bags Market Segmentation

  • By Type
  • Single Chamber
  • Multi-Chamber
  • By Material
  • Ethylene Vinyl Acetate (EVA)
  • Polypropylene (PP)
  • Copolyester Ether
  • By Capacity
  • Up to 50 ml
  • 50 to 100 ml
  • Greater than 100 ml
  • By End-User
  • Hospitals
  • Specialty Clinics
  • Others
  • By Geography
  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. NON-PVC IV BAGS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Single Chamber
  • 5.3. Multi-Chamber

6. NON-PVC IV BAGS MARKET BY MATERIAL

  • 6.1. Introduction
  • 6.2. Ethylene Vinyl Acetate (EVA)
  • 6.3. Polypropylene (PP)
  • 6.4. Copolyester Ether

7. NON-PVC IV BAGS MARKET BY CAPACITY

  • 7.1. Introduction
  • 7.2. Up to 50 ml
  • 7.3. 50 to 100 ml
  • 7.4. Greater than 100 ml

8. NON-PVC IV BAGS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Specialty Clinics
  • 8.4. Others

9. NON-PVC IV BAGS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. India
    • 9.6.3. Japan
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. B. Braun SE
  • 11.2. ICU Medical, Inc
  • 11.3. Fresenius Kabi AG
  • 11.4. Technoflex
  • 11.5. Silica Healthcare Private Limited
  • 11.6. Spirit Medical Limited
  • 11.7. Ningbo Siny Medical Technology Co.
  • 11.8. Rusoma Laboratories Private Limited

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations